A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion

• Status: Completed
• Trial end date: 2015-03-30
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate

Criteria

Inclusion Criteria:

• Diagnosis of macular edema

• Best corrected visual acuity of approximately 20/400 to 20/40 in the study eye

Exclusion Criteria:

• Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month

• Intraocular surgery, including cataract surgery, and/or laser surgery of any type within 3 months

• Any active ocular infection in either eye